CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer

Ryan Cross

Senior Science Correspondent

The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration reveals 'most favored nation' drug price country targets

In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines

Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

RFK Jr. spars with senators over research cuts, HHS budget plan

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

Senior Science Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer